logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11634488 B1

PDFFull Text
Date of Patent:
Apr. 25, 2023

Filed:

Jul. 10, 2018

Treatment of b cell malignancies using afucosylated pro-apoptotic anti-cd19 antibodies in combination with anti cd20 antibodies or chemotherapeutics

Applicant:

International—drug—development—biotech, Lyons, FR;

Inventors:

Claudine Vermot-Desroches, Dardilly, FR;

Chanthy Kong-Flohr, Pontcharra sur Turdine, FR;

Marc Godinat, Tassin la Demi Lune, FR;

Bruno Cavallini, Saint Germain au Mont d'Or, FR;

Assignee:

INTERNATIONAL—DRUG—DEVELOPMENT—BIOTECH, Lyons, FR;

Attorneys:

B. Aaron Schulman, Esq.

Stites & Harbison, PLLC

Primary Examiner:

Nelson B Moseley, Ii

Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61P 35/00 (2018.01); C07K 16/2887 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/41 (2013.01); C07K 2317/52 (2013.01); C07K 2317/732 (2013.01);
Abstract

The invention relates to novel combination therapies involving anti-CD19 antibodies for the treatment of cancer B cells expressing CD19. One preferred method is where the anti-CD19 proapoptotic MAb or a Fc optimized proapototic humanized MAb. In the methods of the present invention some anti-CD20 agents such as Rituxan®, or chemodrugs such as vincristine may be used in combitherapy. The methods of the present invention reduce the levels of B CD19 positive, more particularly in all diffuse large B cells lymphoma (DLBCL) subtypes and in Follicular lymphomas (FL).

Find Patent Forward Citations

Quick Actions:

Vermot-Desroches, Claudine. (2023). Treatment of b cell malignancies using afucosylated pro-apoptotic anti-cd19 antibodies in combination with anti cd20 antibodies or chemotherapeutics (U.S. Patent No. 11634488). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11634488

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…